NeuroPharmac Journal
Gateway to the latest development in the field of Neurosciences and Pharmacology. The NeuroPharmac Journal is an open-access peer-reviewed journal committed to publishing high-quality articles.
NeuroPharmac Journal
Online submission; Wider visibility through open access; Higher impact with wider visibility; Double-blind peer-review: DOI with Crossref; Similarity Index Check
https://doi.org/10.37881/1
NeuroPharmac Journal uses Crossref Content Registration and Digital Object Identifier, an international standard for article identification
On 22 October 2020, the U.S. Food and Drug Administration approved the antiviral drug Remdesivir for use in adult and pediatric patients 12 years of age for the treatment of COVID-19 requiring hospitalization
On 22 October 2020, the U.S. Food and Drug Administration approved the antiviral drug Remdesivir for use in adult and pediatric patients 12 years of age for the treatment of COVID-19 requiring hospitalization
Urgent health challenges for the next decade: WHO; Stopping Infectious diseases
Urgent health challenges for the next decade: WHO; Protecting the medicines that protect us
Urgent health challenges for the next decade: WHO; Earning public trust
FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?
Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health

 

Current Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. The World Health Organization (WHO) has declared the COVID-19 outbreak a pandemic on 11 March 2020 and till the 28th September 2020 WHO reports the 33,034,598 confirmed cases, 996,342 deaths and 213 countries, areas or territories with cases worldwide affected. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19.

On 22 October 2020, the U.S. Food and Drug Administration approved the antiviral drug Remdesivir for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.

WELCOME TO NEUROPHARMAC JOURNAL

Aim and Scope of the Journal

NeuroPharmac Journal is an open-access official peer-reviewed International Journal Publishing three Issues per year and allowing open access to abstracts and full-text. The term “Neuro” is devoted to the promotion of Medical and Healthcare related disciplines like Infectious diseases, Clinical research, Nursing research, Physiotherapy research, Occupational therapy research, Pharmaceutical research, Pharmacognosy & Phytochemistry, Pharmacology and Phytopharmacology, Pharmacy Practice, Clinical & Hospital Pharmacy with focus on various neurology updates on neurological disorders and their management. 

While the term “Pharmac” is related to research, review and current updates in Pharmaceutical Science field including Pharmaceutics, Pharmacology, Pharmaceutical, and Medicinal Chemistry, Pharmacognosy and Phytochemistry, Clinical and Hospital Pharmacy and Pharmaceutical Analysis.

The Journal invites reviews, full-length original research articles, concise reports, case study, short-rapid communications of clinical and experimental nature including modern, traditional and epidemiological studies that contribute significantly to the existing knowledge base or open up new frontiers of knowledge in the field of Neurology (medical) and Pharmaceutical Science.

Review articles based primarily on the author’s own research on internationally important topics will be accepted. Short communications to the editor are also welcome. The primary criteria for acceptance and publication are scientific thoroughness and the potential to advance the field of Medical and Pharmaceutical science.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License. (digital archiving policy= LOCKSS)

 

Announcements
  • News
    Welcome to NeuroPharmac Journal

    Articles are Invited for Volume 5, Issue 3 (September-December 2020)

    To Join Editorial Board or Reviewer: Please email your resume to neuropharmac@gmail.com